ORAL THIN FILMS MARKET ANALYSIS

Oral Thin Films Market Size and Trends

Global oral thin films market is estimated to be valued at USD 3.10 Bn in 2024 and is expected to reach USD 5.80 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 9.4% from 2024 to 2031.

To learn more about this report, request sample copy

Oral thin film drug delivery technology offers advantages over conventional tablets and liquid formulations. Oral thin films are convenient to administer and cause less irritation to the oral cavity as compared to tablets. Rising preference for convenient dosages and technological advancements in thin film drug delivery are expected to drive the market growth during the forecast period. The younger generation populace is inclined toward convenient dosages which is further expected to boost the market growth. pipeline products in clinical trials and new product launches are anticipated to fuel the oral thin films market growth over the forecast timeframe. In January 2022, according to an article published by IntechOpen Oral films composed of composite polymeric matrices serve as effective drug delivery platforms. These matrices, comprising various components, often prioritize hydrophilic polymers. Both the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) define a thin film that quickly dissolves in the oral cavity as an orodispersible film. Initially designed as breath-freshening formulations, oral films rapidly evolved to meet diverse commercial demands, offering a convenient and easily ingestible method for medication delivery.

The increasing prevalence of target ailments and their associated benefits with thin films

The main factors propelling the market are the rising prevalence of target diseases and the benefits of thin films. For instance, according to data provided by Parkinson's Foundation in 2021 reported that over 10.0 million individuals worldwide were affected by Parkinson's disease. According to the same report, approximately 1.0 million Americans had Parkinson's disease in 2021. Furthermore, since Parkinson's disease risk rises with age, it is anticipated that the world's aging population will have a favorable effect on the market. In addition, the 2021 Parkinson's Foundation report projects that the number of individuals with Parkinson's disease will rise to 1.2 million by 2030. One of the most successful therapies for Parkinson's disease is thought to be oral thins. As a result, it is projected that rising rates of Parkinson's disease will fuel the demand for oral thins and accelerate market expansion.

Improving patient compliance due to easy ingestion

The convenience of oral thin films, which dissolve quickly without water, improves patient compliance by addressing swallowing difficulties and offering easy ingestion. This benefits pediatric, geriatric, and other patients who struggle with traditional oral dosage forms. Additionally, the ability to take oral thin films without water enhances medication adherence, especially for patients with limited water access or experiencing nausea. In hospitals, oral thin films simplify administration, contributing to their market growth. For instance, according to an article published by Research gate in February 2021, oral fast-dissolving films offer enhanced patient compliance, rapid release, and improved bioavailability, serving as a cost-effective alternative to conventional dosage forms. They facilitate the delivery of potent medications, extending patent life in the pharmaceutical industry. Recent research supports their industrialization. While offering convenience, their true potential will be realized with more available formulations.